Global health systems partnerships: a mixed methods analysis of Mozambique's HPV vaccine delivery network actors.
Global Health
Government Programs
/ organization & administration
Health Personnel
Health Plan Implementation
Humans
Immunization Programs
/ organization & administration
Intersectoral Collaboration
Mozambique
Papillomavirus Infections
/ prevention & control
Papillomavirus Vaccines
/ administration & dosage
Program Evaluation
Public-Private Sector Partnerships
Qualitative Research
Demonstration project
Gavi
Global health
HPV vaccine
Mozambique
Partnership
SNA
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
received:
11
03
2020
accepted:
19
05
2020
entrez:
7
6
2020
pubmed:
7
6
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Global health partnerships have expanded exponentially in the last two decades with Gavi, the Vaccine Alliance considered the model's pioneer and leader because of its vaccination programs' implementation mechanism. Gavi, relies on diverse domestic and international partners to carry out the programs in low- and middle-income countries under a partnership engagement framework (PEF). In this study, we utilized mixed methods to examine Mozambique's Gavi driven partnership network which delivered human papillomavirus (HPV) vaccine during the demonstration phase. Qualitative tools gauged contextual factors, prerequisites, partner performance and practices while a social network analysis (SNA) survey measured the partnership structure and perceived added value in terms of effectiveness, efficiency and country ownership. Forty key informants who were interviewed included frontline Ministry of Health workers, Ministry of Education staff and supporting partner organization members, of whom 34 participated in the social network analysis survey. Partnership structure SNA connectivity measurement scores of reachability (100%) and average distance (2.5), were high, revealing a network of very well-connected HPV vaccination implementation collaborators. Such high scores reflect a network structure favorable for rapid and widespread diffusion of information, features necessary for engaging and handling multiple implementation scales. High SNA effectiveness and efficiency measures for structural holes (85%) and low redundancy (30%) coupled with high mean perceived effectiveness (97.6%) and efficiency (79.5%) network outcome scores were observed. Additionally, the tie strength average score of 4.1 on a scale of 5 denoted high professional trust. These are all markers of a collaborative partnership environment in which disparate institutions and organizations leveraged each entity's comparative advantage. Lower perceived outcome scores for country ownership (24%) were found, with participants citing the prominent role of several out-of-country partner organizations as a major obstacle. While there is room for improvement on the country ownership aspects of the partnership, the expanded, diverse and inclusive collaboration of institutions and organizations that implemented the Mozambique HPV vaccine demonstration project was effective and efficient. We recommend that the country adapt a similar model during national scale up of HPV vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
Global health partnerships have expanded exponentially in the last two decades with Gavi, the Vaccine Alliance considered the model's pioneer and leader because of its vaccination programs' implementation mechanism. Gavi, relies on diverse domestic and international partners to carry out the programs in low- and middle-income countries under a partnership engagement framework (PEF). In this study, we utilized mixed methods to examine Mozambique's Gavi driven partnership network which delivered human papillomavirus (HPV) vaccine during the demonstration phase.
METHODS
METHODS
Qualitative tools gauged contextual factors, prerequisites, partner performance and practices while a social network analysis (SNA) survey measured the partnership structure and perceived added value in terms of effectiveness, efficiency and country ownership. Forty key informants who were interviewed included frontline Ministry of Health workers, Ministry of Education staff and supporting partner organization members, of whom 34 participated in the social network analysis survey.
RESULTS
RESULTS
Partnership structure SNA connectivity measurement scores of reachability (100%) and average distance (2.5), were high, revealing a network of very well-connected HPV vaccination implementation collaborators. Such high scores reflect a network structure favorable for rapid and widespread diffusion of information, features necessary for engaging and handling multiple implementation scales. High SNA effectiveness and efficiency measures for structural holes (85%) and low redundancy (30%) coupled with high mean perceived effectiveness (97.6%) and efficiency (79.5%) network outcome scores were observed. Additionally, the tie strength average score of 4.1 on a scale of 5 denoted high professional trust. These are all markers of a collaborative partnership environment in which disparate institutions and organizations leveraged each entity's comparative advantage. Lower perceived outcome scores for country ownership (24%) were found, with participants citing the prominent role of several out-of-country partner organizations as a major obstacle.
CONCLUSIONS
CONCLUSIONS
While there is room for improvement on the country ownership aspects of the partnership, the expanded, diverse and inclusive collaboration of institutions and organizations that implemented the Mozambique HPV vaccine demonstration project was effective and efficient. We recommend that the country adapt a similar model during national scale up of HPV vaccination.
Identifiants
pubmed: 32503479
doi: 10.1186/s12889-020-08958-1
pii: 10.1186/s12889-020-08958-1
pmc: PMC7275554
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
862Subventions
Organisme : GAVI Alliance
ID : Not Applicable
Références
Soc Sci Med. 2011 Mar;72(5):798-805
pubmed: 21306807
Implement Sci. 2017 Jan 13;12(1):7
pubmed: 28086813
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:7-14
pubmed: 28691329
Glob Health Action. 2016 Nov 14;9:31899
pubmed: 27846928
Implement Sci. 2015 Apr 21;10:53
pubmed: 25895742
Adm Policy Ment Health. 2012 Jul;39(4):317-20
pubmed: 22240938
Adm Policy Ment Health. 2012 Jul;39(4):301-16
pubmed: 22160786
Vaccine. 2016 Aug 17;34(37):4354-9
pubmed: 27431423
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Glob Health Sci Pract. 2018 Dec 27;6(4):629-634
pubmed: 30459216
Am J Public Health. 2004 Nov;94(11):1922-5
pubmed: 15514228
Implement Sci. 2014 Oct 30;9:126
pubmed: 25358894
BMC Public Health. 2015 Nov 30;15:1198
pubmed: 26621528
Adm Policy Ment Health. 2014 Jan;41(1):74-85
pubmed: 22886317
BMC Health Serv Res. 2012 May 16;12:118
pubmed: 22591757
Vaccines (Basel). 2015 May 20;3(2):408-19
pubmed: 26343194
Vaccine. 2015 Aug 26;33(36):4383-4
pubmed: 25510390
Health Policy Plan. 2012 May;27 Suppl 2:ii1-4
pubmed: 22513728
J Am Assoc Nurse Pract. 2013 Feb;25(2):91-102
pubmed: 23347245
PLoS Med. 2010 Mar 16;7(3):e1000249
pubmed: 20305714
Health Policy Plan. 2012 Aug;27(5):438-46
pubmed: 21840934
Int J Environ Res Public Health. 2018 Mar 13;15(3):
pubmed: 29534038
Global Health. 2016 Apr 29;12(1):14
pubmed: 27129684
Health Policy Plan. 2012 May;27 Suppl 2:ii5-16
pubmed: 22513732
PLoS Med. 2017 Jun 27;14(6):e1002325
pubmed: 28654640
Int J Health Policy Manag. 2016 Oct 26;6(6):327-338
pubmed: 28812825